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1.1	PUBLIC HEALTH BURDEN OF SUBSTANCE USE DISORDERS
The American Psychiatric Association defines addiction as, “a complex condition, a chronic brain disease that is manifested by compulsive substance use despite harmful consequence,” (APA). Symptoms of substance use disorders have four categories. They include drug effects, risky use, social problems, and impaired control. The Substance Abuse and Mental Health Services Administration (SAMHSA) is a federal agency that conducts the National Survey on Drug Use and Health (NSDUH). In the 2015 survey, SAMHSA reported that 20.8 million people aged 12 or older had a substance use disorder in the past year. Of those 20.8 million, 15.7 million had an alcohol use disorder and 7.7 million had an illicit drug use disorder. Overall, healthcare expenditure for substance abuse disorders was reported to cost $24.3 billon 2009 and expected to grow to $42.1 billion by 2020 (SAMHSA). Prevalence rates of some addictive substances such as alcohol and cocaine have been declining in the past decade, while heroin use has been increasing. According to the NSDUH, alcohol use disorders in individuals 18-25 years of age (n=3.8 million) have significantly decreased from 17.7 percent in 2002 to 10.9 percent in 2015 (p<0.05; SAMHSA). The rate of individuals aged ≥26 years (n=11.3 million) have significantly decreased from 6.2 percent in 2002 to 5.4 percent in 2015 (p<0.05; SAMHSA). Similarly results in cocaine use disorders show individuals 18-25 years of age (n=229,000) have significantly decreased from 1.2 percent in 2002 to 0.7 percent in 2015 (p<0.05; SAMHSA). The rate of individuals aged ≥26 years (n=637,000) have significantly decreased from 0.6 percent in 2002 to 0.3 percent in 2015 (p<0.05; SAMHSA). By contrast, results in heroin use disorders show individuals 18-25 years of age (n=155,000) have significantly increased from 0.2 percent in 2002 to 0.7 percent in 2015 (p<0.05; SAMHSA). The rate of individuals aged ≥26 years (n=430,000) was stable at 0.1 percent from 2002 until 2010 (p<0.05; SAMHSA). Then, the rate significantly increased from 0.1 percent in 2011 to 0.2 percent in 2015 (p<0.05; SAMHSA). Consequently, these disorders represent a significant public health burden.
1.2	MECHANISM OF ADDICTION
The mechanisms of addiction have been examined at the molecular level in human and rodent models. Opium and its derivatives act as analgesics and bind to receptors that are normally used by endorphins and enkephalins (sometimes referred to as endogenous opiates)(Sahbaie et al. 2016). Prolonged drug abuse in opioid users results in remodeling of synapses in the central nervous system, referred to as a disorder of experience-dependent neuroplasticity (Russo et al., 2009; Kasenetz et al., 2010). In cocaine addiction, use of the drug blocks the transporter protein channels that would normally return the neurotransmitter, dopamine, to the axon. Instead, the neuron becomes over-stimulated and the result is production of fewer receptors in the postsynaptic membrane (Schmidt et al., 2013). If the user abstains from cocaine use, then normal reuptake of dopamine would continue. Since there are fewer receptors available, the sensitivity of the nerve pathway lessens. Users now need cocaine to maintain normal levels of activity since it intensified their pleasurable sensations. Over time there can be an increased need for a higher and higher dose of the substance to achieve the same level of sensation, known as tolerance (Russo et al., 2009; Liang et al., 2013). Overall, heavy use of these drugs cause long-term damage to the pleasure and reward circuitry of the brain (Kasenetz et al. 2010).
1.3	BEHAVIORAL ASPECTS OF ADDICTION
Characteristics of drug addiction involve a number of behaviors including but not limited to uncontrolled drug consumption, deficits in behavioral inhibitory control, and high rates of relapse in periods of attempted abstinence. Effective inhibitory control is used in everyday life in order to withhold socially inappropriate thoughts such as peculiar or spiteful expressions. Smith et al. (2014) published a meta-analysis of 97 studies that compared addiction-like behaviors or heavy substance abuse users (determined using DSM-IV criteria, n=3405) with healthy controls (no history of substance use, n=3119)(Smith et al., 2014). These studies ranged in participant size from 38 to 620, ranged from zero to seventy-five percent female and included an average age of 50 years (Smith et al., 2014). Using common measures of inhibitory control, Go/NoGo task and Stop-Signal Task, they discovered that inhibitory deficits of significant small to medium effect were present for individuals who exhibited heavy use/dependence on alcohol (g=0.345, p<0.004), tobacco (g=0.248, p<0.037), cocaine (g=0.464, p<0.001), MDMA (g=0.351, p=0.047) and methamphetamine (g=0.724, p<0.001) (Smith et al., 2014). However, they reported no differences in inhibitory deficits between controls and individuals who reported heavy use/dependence on opioids (N=270) or cannabis (N=739) (Smith et al., 2014). This review did not report the geographic location or ethnicity; however, the evidence suggests that some classes of drugs may involve and influence different behaviors. 
Opioids have been recently associated with specific personality characteristics as risk factors for susceptibility to opioid abuse (Zaaijer et al., 2014). The study assessed possible differences in a variety of personality traits between individuals who had taken opioids, but were never-dependent (n=161), and individuals who were dependent and were receiving methadone maintenance or heroin-assisted treatment (n=402) in the Netherlands. Personality traits were assessed using a truncated version of Cloninger’s Temperament and Character Inventory. This population comprised of Caucasian individuals from the Netherlands who were at least 25 years of age with a mean age of 40. Never-dependent opioid users exhibited a tendency to seek novel and/or spiritual experiences, as well as harm avoidance (d=0.49, p<0.0024) (Zaaijer et al., 2014). Interestingly, the never-dependent individuals exhibited higher levels of reward dependence than dependent individuals (d=0.42, p<0.0024); therefore, they may have been protected against opioid dependence as a result. Furthermore as compared to controls, never-dependent opioid users reported higher self-directedness, a measure of self-efficacy, (d=0.55, p<0.0024) (Zaaijer et al., 2014), which may have helped them better adapt and make choices regarding their actions. In addition to reporting lower self-directedness, dependent users reported significantly higher harm avoidance than never-dependent users (d=0.58, p<0.0024) (Zaaijer et al., 2014). These findings are suggested to become important for planning and prevention strategies as part of adolescent assessments for those believed to be at higher risk of opioid dependence. By using this strategy, it could become possible to identify those at risk and target them with prevention efforts to avoid behaviors that could lead to opioid dependence.
2.0 	GENETIC FACTORS OF ADDICTION
2.1	GENETICS INTRODUCTION AND IMPORTANCE IN PUBLIC HEALTH GENETICS
Understanding genetic mechanisms underlies research in all fields of the life sciences. Genes are composed of DNA, deoxyribonucleic acid, which has been referred to as the building blocks of life. Specifically, DNA is composed of two strands of four different molecules called nucleotides. They are cytosine, guanine, thymine, and adenine (C, G, T, A). The central dogma in genetics is that genes (strands of DNA) are transcribed into a copy composed of single-stranded RNA (ribonucleic acid), which is then translated into a protein. Proteins serve roles throughout and between cells as part of life’s functions. Mutations in DNA can lead to significant differences in our appearance and health. These differences appear as a phenotype, defined as the “observable physical and/or biochemical characteristics of the expression of a gene” (NCBI). Study of these factors provides the foundational research, which can then be used for treatment strategies of addiction in some cases. 
Like many fields of science, the study of human genetics is an ever-expanding and continually advancing field. Genetics is defined as the study of genes, their expression and their heredity in organisms. By utilizing this field, it has become possible to understand how traits vary between individuals, how traits are passed to offspring, and influence our mental and physical characteristics. Human genetics has the potential to make a significant difference in public health, specifically by providing foundational research and aiding development of clinical treatment. Genetics has become prevalent in many specialties of science. One such specialty is psychiatrics where research has examined various content areas relating to biologic, social and cognitive functioning (McAdams et al., 2013; Zaaijer et al., 2014). Susceptibility to substance abuse disorders is believed to aggregate in families. Relatives of individuals with suffering from addiction are considered be at, “4-8 fold increase in risk of substance abuse disorders in individuals with an affected first-degree relative,” according to a review by researcher Paul Kenny, PhD (2014). Due to the rising prevalence and public health burden of addiction, understanding the potential mechanisms of psychiatric disorders, such as substance abuse disorders, is beneficial and important to public health. Much of the research into substance abuse disorders began focus in families in which single gene variants (SNPs) were examined and more recently epigenetic mechanisms (discussed later). This would indicate that these disorders could be attributed to multiple factors including those in the environment. 
2.2	INTERACTION OF BEHAVIORAL GENETICS AND ENVIRONMENT
Environmental measures such as parenting and life events may influence (possibly genetically determined) behavioral phenotypes in offspring (McAdams et al., 2013). Using self-report questionnaires, researchers examined a sample of adolescent participants (n=2647) comprising sixty-nine percent female with a mean age of 14.78 (range 13-17, SD=1.36), all monozygotic or dizygotic twin pairs (n=328 and n=774, respectively)(McAdams et al., 2013). Since monozygotic twins share 100 percent of their genetic make-up and dizygotic twins share 50 percent, researchers focused on the role of those shared genetic traits (behavioral phenotypes) in correlation with their experiences of life events and parental negativity. The result showed that negative life events (such as “suspension from school” or “being sent away from home”) showed moderate to strong genetic correlation with depression (0.57[CI: 0.26-0.97], p<0.01), oppositionality (0.95[CI: 0.62-0.99], p<0.01), delinquency (0.99[CI: 0.73-1.00], p<0.01), and physical aggression (0.68[CI: 0.36-0.96], p<0.01) (McAdams et al., 2013). It was hypothesized that humans select, modify, and create environments that are correlated with their genetically determined personality and psychopathology. These correlations are some of the most replicated findings in behavioral genetics, according to a recent review by Plomin et al. (2016). This would support the idea that genes and environment have an interaction that results in observable phenotypes. 
2.3	SINGLE NUCLEOTIDE POLYMORPHISMS RELATED TO ADDICTION
A SNP is a mutation that is a single nucleotide base change in the DNA sequence. SNPs, also called single genetic variants, have been shown to have associations with substance use disorders. Common SNP’s are those that are found occurring frequently (0.05 allele frequency or higher) compared to rare variants in a population. A single common SNP is generally believed to have small effect on phenotypes (Manolio et al., 2009). However, multiple common SNPs added together could potentially have a larger effect (Manolio et al., 2009). In a recent study by Palmer et al. (2015), the effects of common SNPs were examined in a predominantly European ancestry population (n=2596) taken from multiple data sets in the U.S. in which subjects had reported addiction to or problem use of alcohol, tobacco, cannabis, or illicit drugs (Palmer et al., 2015). Their evidence supports that heritability of common SNPs is associated with generalized vulnerability to substance use disorder traits including diagnosed dependence (h2SNP=0.36, SE=0.13, p=2.30x10-3), problem use of substances (h2SNP=0.36, SE=0.13, p=2.30x10-3), and dependence vulnerability (h2SNP=0.36, SE=0.13, p=2.30x10-3) compared to an independent case-controls (Palmer et al. 2015). They attributed at least 20 percent of the general vulnerability to substance dependence to heritability of common SNPs and hypothesized that common SNPs could be used to index the genetic liability of comorbid drug problems. However, the total contribution of all of the variants to the phenotype was modest (25-36%); again indicating that environmental factors have strong effects on susceptibility (Palmer et al., 2015). Similar results have been replicated in a genome-wide association study of alcohol dependence in an African American population (n=2875). Researchers Yang et al. (2014) revealed evidence that their array of 769,498 common SNPs accounted for 23.9 percent (SE=9.3%, p<0.05) of the variance. 
2.3.1	Single SNPs as Risk Factors
Single SNPs can be risk factors for addiction. Strong associations of single SNPs have been found in association with addiction. In a recent candidate gene study of 122 variants in 26 stress-related genes, Levran et al. (2014) uncovered evidence supporting that stress-related genes may contribute to heroin addiction in an African American sample comprising 314 cases (37% female) and 208 controls (52% female)(Levran et al., 2014). Heroin addiction was significantly associated with variants rs1360780 of intron 2 (OR=2.35, pcorrected=0.03) and rs3800373 (OR=2.85, pcorrected=0.0018) of the 3`UTR in the FKBP5 (FK506 binding protein 5) gene, possibly by modulating the stress response (Levran et al., 2014). One of the functions of corticotrophin-releasing hormone (part of the body’s stress response system) is to stimulate the mesocorticolimbic dopamine system, which mediates the rewarding effects associated with drug use. Therefore, these variants of the FKBP5 gene, the product of which functions to co-chaperone regulation of glucocorticoid sensitivity, possibly combined with other stress-related gene variants, could contribute to heroin dependence. Genes in other biochemical pathways have been associated with opioid dependence as well. A recent genome-wide association study (Nelson et al., 2016) reported an association between susceptibility to opioid abuse and variants in the CNIH3 gene in an Australian population (n=1328) comprising individuals 18 years and older that were either opioid-dependent daily injectors or non-dependent users. The CNIH3 (cornichon family AMPA receptor auxiliary protein 3) gene encodes a protein subunit that is part of a receptor in the AMPA glutamate system. Its expression is highest in the frontal cortex, amygdala, and hippocampus; the amygdala is normally associated with habituation. Specifically, results of the study revealed that CNIH3 SNP rs1436175 (OR=0.50[0.39-0.64], p=2.72x10-8) was associated against progression to opioid dependence in opioid users. The AMPA glutamate system is a primary excitatory neurotransmitter system in the central nervous system. Thus, this association is consistent with previous research on the involvement of addiction disorders in synaptic plasticity (Kasenetz et al., 2010). Overall, the above studies indicate that multiple common SNPs of small but additive effect and single SNPs may mediate genetic risk for substance use addiction. However, SNPs may also be protective against substance abuse disorders.

2.4	EPIGENETIC FACTORS RELATED TO ADDICTION
Much of the research into genetic influence on substance abuse disorders includes focus on epigenetic mechanisms such as microRNAs, DNA methylation, or histone modification. Epigenetic refers to epi- meaning “on top of” or “in addition to” and genetics, the study of genes, their heritability in organisms. As opposed to modifications at the nucleotide level of DNA such as a single nucleotide polymorphism, modifications at the chromosomal level occur throughout development; the study of which is known as epigenetics. Epigenetic effects are believed to modify how genes are expressed, either increasing or decreasing expression. In some instances, these changes can increase expression, decrease expression, or silence expression all together. 
One gene in particular has been associated repeatedly with drug addiction, possibly so by epigenetic mechanisms. Epigenetic regulation of the brain-derived neurotrophic factor (BDNF) gene, which is expressed throughout the nervous system, has been the subject of overlapping research in human, rodent and frog studies. The BDNF protein is involved in higher cognitive functions in addition to critical regulation of the structure and function of neuronal circuits (Im et al., 2010). In a recent review of 79 studies, McCarthy et al. (2012) drew attention to the effect by which addictive substances are believed to induce changes in BDNF expression in the mesolimbic dopamine pathway. For example, chronic morphine exposure in a mouse model (n=5 per group) increased BDNF expression 1.5 fold (p<0.01) compared to controls in spinal cord tissue, resulting in persisting neuroadaptations (Liang et al., 2013). Neuroadaptations are changes in the responsiveness of a neuron or neurons in a system to a stimulus, as is the case in chronic exposure to addictive substances; this is the physiological change involved in tolerance. Further research is warranted to elucidate the exact mechanisms.
2.4.1	MicroRNA
MicroRNAs (miRNA) are small non-coding strands of RNA (~19-23 nucleotides in length) that up-regulate or down-regulate gene expression by binding to the 3’ untranslated region (UTR) of their targets, mRNA transcripts. Research has implicated various miRNAs in modulation of cocaine reward and withdrawal (Brown et al., 2013). Expression of one in particular, miR-212, showed a significant reduction (t10=2.876, p=0.01) in the dorsomedial striatum region of the brain of rats phenotyped as addiction-vulnerable (n=6) compared to addiction resilient (n=6)(Quinn et al., 2015). Interestingly, these findings were made up to 8 weeks after drug exposure, which supports the persistent neuroadaptations and propensity of relapse in addicts caused by chronic self-administration of cocaine (Kasenetz et al., 2011). This finding is important since down-regulation of miR-212 in the MeCP2 gene is hypothesized to protect against detrimental cell signaling pathways that result in drug seeking (Im et al., 2010). Other studies of addictive substances have shown similar results. A self-administering methamphetamine rat addiction study (n=22) has shown association with upregulated expression of miR-181a-2 (fold (log2)= -0.69, padj=0.00085) compared to controls as a result within the ventral tegmental area of the brain (Bosch et al., 2015). Even though this study administered short access to methamphetamine (20 daily injections followed by 14 days abstinent) as opposed to chronic exposure (such as daily use for one year), these results show an important role of miRNAs having influence in vulnerability to addiction (Bosch et al., 2015). Association between alcohol use disorder and miRNA has been identified (Lewohl et al., 2011). Using human brain tissue from former alcoholics (n=14, WHO criteria: average 80kg per day alcohol consumption) compared to sex-matched controls (n=13, WHO criteria: <20kg per day alcohol consumption), expression of 48 miRNAs was significantly increased (mean 27±11%, p<0.005) with miR-1 having been increased the most (45%, padj=0.044) in association with alcohol dependence (Lewohl et al., 2011). Another study of short term (1 hour) alcohol exposure has shown the modularity of miRNA expression in relation to the big potassium (BK) channel, a protein that plays a dominant role in shaping neuronal activity and is strongly influenced by alcohol consumption (Pietrzylowski et al., 2008). This in vitro study, involving the regulation of miR-9 expression, revealed an increase of miR-9 expression in neurons of the supra-optic nucleus (50%, p<0.05) and the striatum (2 fold, p<0.05) of rats (n=27) compared to saline controls while BK transcripts decreased 80 percent (p=0.01)(Pietrzylowski et al., 2008). This rapid response to alcohol is important to note, since the BK channel has very high conductance and its dysfunction could result in serious consequences for the central nervous system. Although many studies report associations between miRNA expression and alcohol use disorders, the exact mechanisms underlying these associations are unclear. However, increased mi-RNA expression is considered to result in decreased protein expression, which can lead to neural deterioration (Most et al., 2014). Overall, miRNAs modulate gene expression in cases of chronic use of addictive substances. 
2.4.2	DNA Methylation
Another type of epigenetic mechanism is DNA methylation. DNA methylation is the process of methyl groups being added to DNA, cytosine and guanine dinucleotides. These small changes may repress gene expression and thus, significantly impact a trait. Knothe et al. (2016) examined the potential role of DNA methylation regulating expression of the mu-opioid receptor gene, OPRM1. Using human cell lines, mRNA expression and methylation levels were examined in the non-neuronal mu-opioid receptor non-expressing HEK-293 cell line, the mu-opioid receptor expressing neuronal-derived SHSY5Y cell line, and the neuronal mu-opioid receptor non-expressing Kelly cell line. Over their 22 selected CpG positions, findings included OPRM1 methylation in Kelly cells to be higher on average (80% C-methylation, F=216.7, p<0.001) compared to SHSY5Y cells (3% C-methylation, F=216.7, p<0.001) (Knothe et al., 2016). This corresponded to no OPRM1 mRNA expression in Kelly cells (none compared to β-actin, F=63.72, p<0.0001) compared to OPRM1 mRNA expression levels in SHSY5Y cells (5.9x10-6 compared to β-actin, F=63.72, p<0.0001) (Knothe et al., 2016). These differences suggest that epigenetic regulation of the mu-opioid receptor through changes in DNA methylation does occur. They also highlighted the possibility that effects of other epigenetic mechanisms could mask the effects of DNA methylation. In a mouse model of cocaine administration and protracted abstinence (N=53), researchers Baker-Andresen et al. (2015) found persistent methylation changes in neuronal DNA isolated from the medial prefrontal cortex. Following 10-12 days of cocaine self-administration, mice were abstinent for 21 days and given a relapse test to expressly reactive cocaine memories. Findings revealed a demethylation (-37.5% relative 5mC enrichment) of the Golgb1 gene compared to naïve mice (F3,17=3.57, p<0.05) (Baker-Andresen et al., 2015). This decrease was correlated with a decrease in Golgb1 gene expression (-20% relative expression) compared to naïve mice (F3,26=5.42, p<0.01) (Baker-Andresen et al., 2015). This evidence suggests that altered DNA methylation could cause long-term abstinence associated behavioral adaptations such as maintenance of cocaine-related memories and continued cocaine seeking. Overall, research supports that DNA methylation is involved in epigenetic gene expression and associated aspects of addiction including self-administration and abstinence.

2.4.3	Histone Modification
Another type of epigenetic mechanism is histone modification. Histones are proteins that package the DNA so that it can be stored into compact structural units, and they play a role in gene regulation. Histone modifications include acetylation, phosphorylation and ubiquitination. Histones can become acetylated or de-acetylated via specific enzymes such as HAT (histone acetyltransferase) or HDAC (histone deacetylase), which is important since this is the manner in which genes can be expressed or not. Increased acetylation is considered to increase expression while decreased acetylation decreases expression (Schmidt et al., 2013). Increased acetylation (3.5 fold enrichment, p<0.001) of the histone H3K9 was shown to be associated with morphine in up-regulating expression of the BDNF (3 fold, p<0.001) and PDYN (5 fold, p<0.001) genes, which are implicated in neuronal pathways (Sahbaie et al., 2016). This discovery was made while investigating enhanced postoperative pain and analgesic tolerance after continuous opioid exposure in their mouse model (n=5 per group). Other examples of histone acetylation have been implicated in a heroin self-administration rat model (n=21; Xu et al., 2016). Compared to passive yoked controls, an association between heroin self-administration and deacetylation of histone H4K5 (2.44 fold, p=0.013) in relation to BRG1 gene expression was found in a specific brain region of the mesocorticolimbic dopamine system known as the ventral tegmental area (VTA) (Xu et al., 2016). Their results implicated heroin administration, not specifically addiction in this study, but the association is another example of histone acetylation exerting an influence relating to gene expression. Other areas of the central nervous system show changes in gene expression resulting from histone acetylation (Liang et al., 2013). In another mouse model (n=5 per group) of opioid-induced hyperalgesia (abnormally heightened sensitivity to pain), dependence and tolerance, resulting evidence supported acetylation of histone H3 in the dorsal horn of the spinal cord being increased (2 fold, p<0.05) after chronic opioid exposure (Liang et al., 2013). This would suggest that these associations between histone acetylation and opioid dependence occur through the central nervous system. Overall, histone modifications, specifically acetylation, are implicated in epigenetic gene expression and associated addiction, though the exact mechanisms require further research.
As described above, the additive effects of multiple genetic variants, as well as, epigenetic mechanisms involving miRNA, histone modification, and DNA methylation have been associated with substance use disorders in multiple studies involving human and rodent models. Further research is warranted to determine the details of underlying mechanisms of susceptibility to addiction. 
3.0 	EXAMINING THE OPIOD EPIDEMIC
3.1	OPIATES
The poppy plant is the natural source of opium and has been commonly used for hundreds of years. Opium and its derivatives including morphine and codeine have been used for medicinal purposes and are considered to be unsurpassed in terms of pain management. Additionally, opioids are prescribed for a variety of other symptoms such as cough and diarrhea. Their effects include feelings of sedation, tranquility and euphoria. As mentioned previously, they are highly addictive and exhibit tolerance in humans as well as animal models. In higher doses, they lead to such levels of sedation that will overwhelm respiratory functions and result in death (Schuckit, 2016). 
3.2	TREATMENT
Physical dependence can be treated using administration of methadone and buprenorphine by specialty programs. These treatments must be administered by physicians and other healthcare professionals with specialty training and comprise a gradual reduction of doses over the course of weeks in a controlled environment. An alternative method to facilitate withdrawal utilizes a combination of α2-adrenergic antagonists, benzodiazepines, loperamide, prochlorperazine, sports drinks or intravenous fluids, and non-steroidal anti-inflammatory agents. In addition, emotional and psychological support through self-help programs and education help to rehabilitate former users (Schuckit, 2016). 
3.3	RISING PROBLEM
In recent years, rising levels of opiate overdose related death has garnered the attention of public health agencies. The Substance Abuse and Mental Health Services Administration (SAMHSA) is a federal agency that conducts the National Survey on Drug Use and Health (NSDUH). In the 2015 survey, SAMHSA reported that 20.8 million people aged 12 or older had a substance use disorder in the past year. Of those 20.8 million, 2 million people had a pain reliever use disorder and 591,000 had a heroin use disorder. SAMHSA also reported that there has been a statistically significant increase in heroin use disorders from 2010 compared to 2015. Part of the NSDUH includes regional maps which indicate that annual averages from 2012-2014 showed that the region of Allegheny County reported that the percentage of persons who reported illicit drug dependence or abuse in the past year was 3.16-3.46 percent; the majority of the Commonwealth of Pennsylvania (PA) was 2.82 percent or lower (SAMHSA). In 2013, the CDC reported that the rate of drug poisoning deaths in PA was 19.4, higher than the U.S. rate of 13.8 (CDC, 2013). Community-based partnerships have begun to emerge as a result. OverdoseFreePA is a collaboration of six partner organizations and sixteen Pennsylvania communities that seek to increase awareness and support initiatives to address the issue of substance use disorders. Data on unintentional overdoses is collected from death records submitted from the county coroner and medical examiner’s office. Their data reflects the increasing prevalence of heroin related overdoses in Allegheny County. Between the years 2008-2016, heroin is reported as the leading substance in overdose death; it comprises 1240 deaths out of an overall 2310 (53.7%) total substance overdose deaths (OverdoseFreePA, 2016). 
3.4	CONTRIBUTING FACTORS
The rise of what is now known as the opiate epidemic has been supported by a number of factors. Journalist and author Sam Quinones (2015) investigated the problem in depth in his work Dreamland: The True Tale of America’s Opiate Epidemic. Through his comprehensive analysis of the issue, Quinones found that black tar heroin has been an illicit opiate that contributed significantly to this issue. Its production and efficient distribution allowed its sale to reach across the U.S. (Quinones, 2015).
Another main contributing factor to the opioid epidemics is over-prescription for medical uses. Research from the CDC regarding this matter has been published in their Morbidity and Mortality Weekly Report (MMWR). The CDC examined data from the IMS Health’s National Prescription Audit. They discovered that variation exists among states in prescribing opioid pain relievers. Out of the estimated 258.9 million prescriptions written in 2012, prescribers wrote 82.5 opioid pain reliever prescriptions per 100 persons in the United States and the rates between states varied 2.7 fold. The three highest prescribing states were Alabama, Tennessee, and West Virginia. The CDC concluded that the high rates indicated need to identify prescribing practices, since practitioners may not be appropriately balancing patient safety and pain relief (CDC, 2014). 

3.5	POLICY REGARDING THE OPIOID EPIDEMIC
3.5.1	Comprehensive Addiction and Recovery Act Of 2016
Health policy at the federal level has been implemented via the Comprehensive Addiction and Recovery Act of 2016 (CARA, S. Bill. 524, 2016) that was recently passed in July 2016. This law responds to the growing epidemic from various perspectives. Title I calls for implementation of a task force of agencies including Health and Human Services (HHS), Department of Justice (DOJ), Department of Veteran Affairs (VA), Drug Enforcement Administration (DEA), and Centers for Disease Control and Prevention (CDC). Title I focuses on prevention and education through expansion of community-based coalitions and awareness campaigns. Title II focuses on law enforcement and treatment through development of treatment alternate to incarceration programs, first responder training of naloxone use, prescription drug take back expansion and specific heroin and methamphetamine task forces. Title III focuses on treatment and recovery through expanding evidence-based prescription opioid and heroin treatment interventions, criminal justice medication assisted treatment and interventions, national youth recovery initiative, and building communities of recovery. Title IV addresses collateral consequences through implementing correctional education demonstration programs and creating a national task force on recovery and collateral consequences. Title V focuses on addiction and recovery services for women, families, and veterans through improving treatment for pregnant and postpartum women, collecting reports on grants for family-based substance abuse treatment and veterans treatment court changes. Title VI focuses on incentivizing state comprehensive initiatives to address prescription opioid and heroin abuse through implementing state demonstration grants to prepare comprehensive state or local government plans to combat the issue. Title VII contains miscellaneous sections including programs to prevent prescription drug abuse under Medicare as well as reports regarding the impact of Medicaid Institutions for Mental Disease exclusion has on access to treatment. Title VIII focuses on transnational drug trafficking by outlawing possession, manufacture or distribution for purposes of unlawful importations (S. Bill. 524, 2016). CARA is comprehensive in its approach and outlines expansion of existing policy at the state and local level. Major health policy examples include naloxone distribution programs, prescription drug monitoring programs, and Good Samaritan laws. 
3.5.2	Prescription Drug Monitoring Programs
One potential policy response to address this problem is use of Prescription Drug Monitoring Programs (PDMP), which are state-based databases of prescriber, dispenser and patient information. As of May 2016, 49 states and the District of Columbia have operational programs; Missouri is the only state that does not (NAMSDL). In a separate report, the CDC analyzed data from the Florida Medical Examiners Commission and prescription drug monitoring policy changes. In 2010, Florida’s state legislature made policy changes by implementing laws that regulated pain clinics. In 2011, new policy prohibited prescribers from dispensing opioid analgesics from their offices, and dispensers were required to report data to the newly established Prescription Drug Monitoring Program. Between 2010-2012, their overdose death rate for opioid analgesics declined from 13.6 to 9.9 per 100,000 persons, a 27.0% decrease, and the overall drug overdose death rate declined from 17.0 to 14.0 per 100,000 persons, a 17.7% decline (CDC, 2014). Other states have seen similar results. The Prescription Drug Monitoring Program Center of Excellence (PDMPCOE) at Brandeis University is a project funded by the U.S. Department of Justice, Bureau of Justice Assistance. The Center of Excellence released a briefing in 2016 showing similar results in Kentucky, Tennessee, New York and Ohio. In each state example, PDMP enrollment increased while prescriptions dispensed decreased, following legislation that mandated use of PDMPs. In 2012, Kentucky passed legislation requiring prescribers to enroll and utilize its PMDP. Enrollment increased from 7,911 users in April 2012 to 25,409 users in July 2013, a three-fold increase. Dispensed controlled substances declined from 7.39 million doses in a one-year period (August 2011-July 2012) to 6.76 million doses in the next year period (August 2012-July 2013), an 8.5 percent decrease. In January 2013, Tennessee passed legislation requiring prescribers to enroll in and utilize its PMDP. Enrollment increased from 15,232 providers in 2011 to 42,835 providers in 2015. The number of opioid prescriptions reported declined from 8,778,561 in 2012 to 8,084,981 in 2015, an 8 percent decrease. In June 2013, New York passed legislation requiring prescribers to enroll in and utilize its PMDP. Enrollment increased from 5,087 users in August 2013 to 67,779 users in February 2014, a 6 month time period. The number of all opioid prescriptions reported declined 9.5 percent. In October 2011, Ohio passed legislation requiring licensing boards to create regulations for prescribers to enroll in and utilize its PMDP. The number of reports queried increased from 911,000 in 2010 to 7.3 million in 2013. The number of hydrocodone doses dispensed declined 3.5 percent and the number of prescriptions declined 11.1 percent. The number of oxycodone doses dispensed declined 1.7 percent and the number of prescriptions declined 8.7 percent (PDMPCOE, 2016). 
Prescription Drug Monitoring Programs (PDMP) have been in effect for a number of years. Recent changes in health policy have called for their expansion (CARA).  Pennsylvania’s Prescription Drug Monitoring Program collects information on all filed prescriptions for controlled substances in an effort to allow healthcare providers to safely prescribe controlled substances such as opioid pain medication. The General Assembly of the Commonwealth of Pennsylvania signed into law Act 191 (S. Bill. 1180, 2014) in 2014, attempting to achieve better care by monitoring. Prescribers are required to query the system for each patient the first time the patient is prescribed a controlled substance or if the prescriber has reason to believe that a patient is abusing a controlled substance. The prescriber may then enter information into a patient’s medical record if the patient shall not be prescribed or furnished a controlled substance based on information found in the system. Dispensers are required to provide the full name of the prescriber, their DEA registration number, the date the prescription was written, the date it was prescription was dispensed, the quantity and days’ supply, the DEA registration number and National Provider Identifier of the dispenser, and method of payment. Furthermore, the full name, date of birth, gender and address of the person for whom the prescription was written and dispensed is also required (S. Bill. 1180, 2014). 
3.5.3	Naloxone Overdose Prevention Law
Naloxone, or Narcan, is a life-saving drug that is effective in stopping and reversing the effects of an opioid overdose (Wermling, 2015). Naloxone has become a mainstay of emergency response as evidenced by its inclusion in federal policy, CARA, and PA health policy. There are a total of 46 jurisdictions that have naloxone overdose prevention laws, including the aforementioned PA and also the District of Columbia. Senate Bill 1164 of the General Assembly of the Commonwealth of Pennsylvania signed into law Act 139 (P.L. 2487) in 2014 regarding Naloxone distribution and drug overdose response immunity. The act authorizes law enforcement officers and firefighters who have completed proper training to administer Naloxone to an individual believed to be undergoing an opioid-related drug overdose. Act 139 of 2014 has authorized a Standing Order DOH-002-2016, which permits healthcare professionals otherwise authorized to prescribe Naloxone to prescribe it via standing order. It permits individuals to obtain Naloxone from a pharmacy in the event that they cannot obtain it from their regular healthcare provider or another source. The Act provides immunity from prosecution for any person who calls for emergency services and stays with the affected individual until they arrive, and it prohibits prosecution against parole violations. Furthermore, the Act prohibits prosecution of persons experiencing drug overdose events. This part of the law would be referred to as Good Samaritan overdose prevention (S. Bill. 1164, 2014). 
3.5.4	Good Samaritan Overdose Law
Good Samaritan overdose laws were created to provide some form of immunity from prosecution for individuals who call emergency responders in cases of illicit drug overdoses. The manner in which these laws are written varies by state. As of July 2016, there are 36 jurisdictions that feature some form of these laws (see Tables 1 and 2). Pennsylvania is one of them, joined by Kentucky, Florida, New York, and Tennessee. It is noteworthy that some of these states are also the ones that have shown success in PDMP implementation. By contradiction, Ohio does not have Good Samaritan laws in effect, as of July 2016 (see Table 2)(Legal Science, 2016).
3.5.5	Allegheny County Naloxone Standing Order
At the local level, health policy in Allegheny County has been implemented in response to this rising problem. As of 2015, Dr. Karen Hacker, the director of the Allegheny County Health Department (ACHD), issued a countywide standing order, citing PA Act 139, to allow pharmacists throughout the county to distribute Naloxone without a prescription. The only other of the 67 counties in PA that has a similar standing order is Montgomery County (ACHD, 2015).
4.0 	DISCUSSION
Substance use disorders comprise a significant public health burden in the U.S. In the National Survey on Drug Use and Health of 2015, the Substance Abuse and Mental Health Services Administration reported that 20.8 million Americans had a substance use disorder, which cost $24.9 billion in healthcare expenditure. Recent studies have revealed that many factors including genetic, behavioral and environmental contribute to the development and maintenance of addiction. Inhibitory control deficits are present in individuals who exhibit heavy use or dependence on alcohol, tobacco, cocaine, MDMA, and methamphetamine, but not on opioids or cannabis (Smith et al., 2014). Substance use disorders are believed to aggregate in families, suggesting a genetic component. First-degree relatives of affected individuals are believed to be at 4-8 fold increased risk of developing of substance use disorders (Kenny, 2014). Environmental measures such as parenting or life events may influence genetically determined behavioral phenotypes (McAdams et al., 2013). The BDNF gene has been the subject of overlapping research in which its epigenetic regulation is associated with drug addiction (McCarthy et al., 2012). The additive effects of multiple common SNPs have been evidenced showing modest heritability of susceptibility to substance use disorders (25-36%; Palmer et al., 2015). Additionally, single SNPs in the FKBP5 gene have shown to be risk factors for addiction, while a SNP in the CNIH3 is associated with protection against opioid dependence (Levran et al., 2014; Nelson et al., 2016). Epigenetic mechanisms involving expression miRNAs miR-9, miR-181, miR-1, and miR-212 have shown association with addiction (Pietrzylowski et al., 2008; Lewohl et al., 2011; Bosch et al., 2015; Quinn et al., 2015). Histone modification including acetylation of histone protein H3K9 and deacetylation of histone protein H4K5 has been associated with opioid addiction (Liang et al, 2013; Sahbaie et al., 2016; Xu et al., 2016). Furthermore, increased DNA methylation of the OPRM1 gene and demethylation of the Golgb1 gene has been associated with substance use disorders as well (Baker-Andresen et al., 2015; Knothe et al., 2016). However, all of these genetic factors do not fully explain the addiction phenotype, which means the combination of genetic and environmental factors play a role. It is difficult to say just how much is attributed to each, but studies support that 20 to 30 percent of the susceptibility could be due to genetic factors while the other 70 to 80 percent could be attributed to environmental. Further research is necessary to determine the details of the exact mechanisms that underlie susceptibility to addiction. 
Utilizing evidence-based policy can have an impact on public health outcomes, such as the successful cases of Prescription Drug Monitoring Programs in Florida, Tennessee, New York, Kentucky and Ohio. Concern over rising levels of opioid-related overdose death has warranted changes in health policy. This essay has highlighted health policy at the federal, state, and local level regarding the opioid epidemic. The Comprehensive Addiction and Recovery Act of 2016 is an example of recent federal level policy recently passed to address the issue of the rising opioid epidemic. Health policy at the state level has also responded, such as Pennsylvania’s Act 139 (S. Bill. 1164, 2014). Interestingly, 46 jurisdictions feature Naloxone overdose prevention laws but only 36 of them feature Good Samaritan provisions that allow protective immunity for those involved in an opiate overdose. New Mexico was the first state to pass this type of law in 2007. By comparison, PA passed these laws in 2014. Even though their intent is similar, that is to address the epidemic, not all of these Naloxone state laws are exactly the same. If law enforcement responds to your overdose in Pennsylvania you will not be charged for possession of an illicit opiate. If you have an overdose involving an illicit overdose in Ohio though, you can be charged for possession of that substance. The Good Samaritan provisions may foster change in the health outcomes of this rising problem. Regardless of good intention, unintended consequences will arise as a result of these policies. In an effort to deter abuse of prescription opioid OxyContin, a new formulation of the pharmaceutical was released in 2010. It was made more insoluble so that it cannot be crushed and dissolved into saline solution for injection like heroin (Dart et al., 2015). Interestingly, the National Poison Data System and Poison Center Program released data showing a spike in the rate of heroin use from 0.12 per 100,000 population in 2010 to 0.23 per 100,000 population in 2013, while the rate of OxyContin Abuse decreased from 0.07 per 100,000 population in 2010 to 0.02 per 100,000 population in 2010 (Dart et al., 2015). Nevertheless, evidenced-based policies provide a promising start, which was the case in the Prescription Drug Monitoring Programs in Florida, Tennessee, New York, Kentucky and Ohio. The combination of these policies may come together to have the synergistic effect in reducing the opioid epidemic. In essence the future of the opiate epidemic looks promising being that government attention along with community partnerships can make a difference.







Table 1. State Overdose Prevention Legislation Summary
Type of Legislation	% of Jurisdictions (number)
Naloxone Overdose Prevention	90.1   (46)
Good Samaritan Overdose Protection	70.5   (36)
PDMP	98      (50)
Percentage of U.S. jurisdictions (50 states and District of Columbia) that include some form of 
Naloxone overdose prevention law, Good Samaritan overdose protection law, and enacted
Prescription Drug Monitoring Programs (PDMP) as of 2016.

Table 2. Pennsylvania Compared to Selected States
State	Naloxone(year effective)	Good Samaritan (year effective)	PDMP (year mandatory)
Pennsylvania	Yes (2014)	Yes (2014)	Yes (N/A)
Ohio	Yes (2015)	No	Yes (2011)
Tennessee	Yes (2015)	Yes (2016)	Yes (2013)
Kentucky	Yes (2015)	Yes (2015)	Yes (2012)
Florida	Yes (2016)	Yes (2012)	Yes (2010)
New York	Yes (2016)	Yes (2015)	Yes (2013)
Pennsylvania compared to selected states that feature some form of Naloxone overdose prevention law, Good Samaritan overdose protection law, and enacted Prescription Drug Monitoring Programs as of 2016. States were selected based on their reported success, highlighted by the Centers for Disease Control and Prevention, in decreasing opioid prescriptions and/or doses dispensed following mandatory enrollment in a Prescription Drug Monitoring Program (PDMP).
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